Document is current
Any future updates will be listed below
-
Authors
Weishaupt, Jochen H.
Körtvélyessy, Péter
Schumann, Peggy
Valkadinov, Ivan
Weyen, Ute
Hesebeck-Brinckmann, Jasper
Weishaupt, Kanchi
Endres, Matthias https://orcid.org/0000-0001-6520-3720
Andersen, Peter M. https://orcid.org/0000-0003-0094-5429
Regensburger, Martin https://orcid.org/0000-0002-2172-7386
Dreger, Marie https://orcid.org/0000-0001-6215-0416
Koch, Jan C.
Conrad, Julian
Meyer, Thomas
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
- License Information
-
More Information
Article History
Received: 14 January 2024
Accepted: 5 July 2024
First Online: 25 July 2024
Competing interests
: The authors declare the following competing interests: T.M. is on the advisory board of Biogen and has received consulting fees from Biogen. P.K. received consulting fees from Biogen. S.P. has participated on advisory boards of Biogen and has received consulting fees from Biogen. T.M. and C.M. are founders and shareholders of the Ambulanzpartner Soziotechnologie APST GmbH, which makes the internet platform Ambulanzpartner and the mobile application ALS-App. APST received a research grant from Biogen. P.M.A. has served on paid advisory boards for Biogen, Roche, Arrowhead, Avrion, Regeneron, uniQure, Voyager and Orphazyme A/S; he has been clinical trial site investigator for AB Science, AL-S Pharma and Lilly, Amylyx, Alexion Pharmaceuticals, Biogen Idec, IBT-Med, IONIS Pharmaceuticals, Orion Pharma, PTH Pharmaceuticals and Sanofi. He is external advisor to the European Medicine Agency. All other authors declare no competing interest.
